2 Minute Medicine

No Result

View All Result

No products in the cart.

2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑

Home StudyGraphics

#VisualAbstract: Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis

byWinnie LiuandMinjee Kim

November 7, 2023

in StudyGraphics

Reading Time: 1 min read

#VisualAbstract: Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis

Click here to read this study in NEJM.

©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

RELATED REPORTS

Telitacicept may reduce proteinuria in patients with high-risk IgA nephropathy

Sparsentan (Filspari) becomes first approved treatment for focal segmental glomerulosclerosis

2 Minute Medicine: Pharma Roundup – Geopolitical instability in the Strait of Hormuz threatens global generic drug supply, daraxonrasib improves pancreatic cancer survival, sparsentan (Filspari) approved for focal segmental glomerulosclerosis, glucagon-like peptide-1 receptor agonists linked to reduced substance use disorders, and orforglipron (Foundayo) expands oral weight loss therapy options

Tags: eGFR focal segmental glomerulosclerosis irbesartan sparsentan

Spiritual health may be high among cancer patients in drug clinical trials

Myocardial viability testing does not identify patients who benefit from percutaneous coronary intervention

RelatedReports

Being overweight and obese associated with increased incidence of chronic kidney disease

Chronic Disease

Telitacicept may reduce proteinuria in patients with high-risk IgA nephropathy

Tenofovir disoprovil fumarate HIV prophylaxis linked with minimal kidney impact

Nephrology

Sparsentan (Filspari) becomes first approved treatment for focal segmental glomerulosclerosis

2 Minute Medicine: Pharma Roundup: Price Hikes, Breakthrough Approvals, Legal Showdowns, Biotech Expansion, and Europe’s Pricing Debate [May 12nd, 2025]

Pharma

2 Minute Medicine: Pharma Roundup – Geopolitical instability in the Strait of Hormuz threatens global generic drug supply, daraxonrasib improves pancreatic cancer survival, sparsentan (Filspari) approved for focal segmental glomerulosclerosis, glucagon-like peptide-1 receptor agonists linked to reduced substance use disorders, and orforglipron (Foundayo) expands oral weight loss therapy options

#VisualAbstract: Atrasentan Reduced Proteinuria in IgA Nephropathy

StudyGraphics

#VisualAbstract: Atrasentan Reduced Proteinuria in IgA Nephropathy

November 4, 2024

Next Post

Appropriate use criteria for angiography may frequently miss obstructive coronary artery disease

Myocardial viability testing does not identify patients who benefit from percutaneous coronary intervention

Adalimumab aids in control of noninfectious uveitis

Avacincaptad pegol reduces the rate of age-related macular degeneration in geographic atrophy

American Academy of Pediatrics recommends standards for adverse event disclosures

Factors important for health-related quality of life in men and women

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

No Result

View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.